When Should You Start Hormone Replacement Therapy (HRT)?

Should I start HRT? — an Introduction

It usually starts quietly. A woman in her late 40s wakes at 3 a.m., soaked through her shirt. The next day she snaps at her kids, forgets a word in a meeting, and wonders whether she's simply burned out. Her periods are still coming, but subtle shifts seem to be occurring. Eventually comes the question that brings most women to a menopause clinic:

"Should I start hormone therapy now, or should I wait?"

Timing is one of the most important and most misunderstood parts of menopause care. For two decades, many women were told to hold off or tough it out. The research now tells a more nuanced story: when hormone therapy is started matters nearly as much as whether it is started.

A note on terms: "HRT" (hormone replacement therapy) and "MHT" (menopausal hormone therapy) mean the same thing.

What is Hormone Replacement Therapy?

HRT isn't one medication. It's a category of medical treatment, and the pieces can be mixed and matched.

The hormones

• Estrogen does the symptom work treating hot flashes, night sweats, vaginal dryness.

• Progesterone (or a progestogen) protects the lining of the uterus (the endometrium). Estrogen alone thickens that lining over time and raises endometrial cancer risk, so any woman with a uterus who takes systemic estrogen also needs a progestogen. Women who've had a hysterectomy do not need a progestogen, but may still consider it for potential sleep and mood benefits. "Micronized progesterone" is a body-identical form, different from synthetic progestins like medroxyprogesterone acetate (MPA), the type used in the large Women's Health Initiative study. [1]

How estrogen is delivered

• Transdermal (patch, gel, spray) bypasses first-pass processing by the liver and appears to carry a lower blood-clot risk than pills. This is the preferred route for women with elevated clot risk, high blood pressure, obesity, or metabolic syndrome, based largely on observational data rather than head-to-head trials. [1]

• Oral estrogen is effective and well studied, but carries higher venous thromboembolism (blood clot) risk.

• Vaginal estrogen is a different treatment entirely. Creams, inserts or low dose vaginal rings work locally for dryness, painful sex, and recurrent urinary tract infections with very little absorbed into the bloodstream. It's not considered systemic therapy and doesn't require a progestogen.

Key takeaway: HRT is flexible, not a single pill. Vaginal estrogen for local symptoms is a separate decision from systemic therapy.

The "Window of Opportunity": What the Research Shows

Women who begin hormone therapy before age 60, or within 10 years of their final period, generally get the most favorable balance of benefits to risks. [1]

This is the position of The Menopause Society (formerly NAMS) in its 2022 Hormone Therapy Position Statement: for women under 60 or within 10 years of menopause onset, with no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes/night sweats and for preventing bone loss. Beyond that window, the same statement notes the balance becomes less favorable, because absolute risks of coronary heart disease, stroke, blood clots, and dementia are higher. [1]

Why timing may matter

Around menopause, arteries are usually still flexible and their inner lining largely intact. In this setting, estrogen appears to support blood vessel function, reduce inflammation, and improve cholesterol profiles. Once significant plaque has built up (typically after many years of estrogen deficiency) the effect may reverse, with estrogen potentially destabilizing established plaque and increasing clotting tendency. This explanation is plausible and widely cited, but remains a hypothesis requiring further research. [2]

The trials

The Women's Health Initiative (WHI) is the study that changed everything in 2002, and was widely misread. It enrolled more than 27,000 women aged 50 to 79, average age about 63, and tested oral conjugated equine estrogen (CEE) with or without MPA. It was designed as a chronic disease prevention trial in largely older women, not a symptom trial in newly menopausal women. [3][4]

Overall, oral CEE with or without MPA increased blood clots and stroke, and CEE plus MPA increased breast cancer. Neither regimen significantly increased coronary heart disease overall. Age-stratified re-analyses showed outcomes differed substantially by age at randomization: women aged 50 to 59, particularly on estrogen alone, had more favorable results for the global index, heart attack, and total cancer than women in their 60s and 70s. [3] The WHI investigators summarize the practical lesson plainly: attributable risks in early menopause are generally under 1 additional adverse event per 1,000 women per year, while symptom relief can meaningfully improve quality of life. They also caution that WHI findings should not be applied to women with premature or early menopause (age 45 or younger), who weren't studied. [4]

ELITE, published in the New England Journal of Medicine in 2016, was designed specifically to test the timing hypothesis. It randomized 643 healthy postmenopausal women (split into those under 6 years past menopause and those 10 or more years past) to oral 17β-estradiol 1 mg daily or placebo. After a median of 5 years, the effect on carotid artery wall thickening differed significantly between groups (P = 0.007 for interaction). In the early group, progression was slower on estradiol (0.0044 vs 0.0078 mm/year; P = 0.008). In the late group, no difference. Notably, CT measures of coronary calcium and plaque didn't differ in either group. [2]

KEEPS, a 4-year trial in 727 recently menopausal women using lower-dose oral CEE and an estradiol patch, found no significant slowing of carotid thickening. Why KEEPS and ELITE differ isn't fully clear; the lower estrogen dose is one proposed explanation. [6]

A Cochrane meta-analysis cited by the American Heart Association found that among women starting under 60 or within 10 years of menopause, coronary heart disease risk was roughly halved (RR 0.52; 95% CI 0.29–0.96) and all-cause mortality reduced 30% (RR 0.70; 95% CI 0.52–0.95), with increased clot risk (RR 1.74) and no excess stroke. Among later starters, there was no cardiovascular benefit, but there were increased stroke and clot risks. [7]

Key takeaway: Starting before 60 or within 10 years of menopause is where the safety profile is most favorable.

Can I Start HRT Before My Periods Stop?

Yes. There's no requirement to wait 12 months after your last period.

Perimenopause (the transition leading up to that final period) can last several years, and hormone levels don't decline smoothly. They swing erratically, which is often why this phase feels worse than the years after menopause. Common symptoms include: irregular or heavier periods, hot flashes, night sweats, 3 a.m. waking, new anxiety or irritability, brain fog, joint aches, vaginal dryness, and reduced libido.

The contraception piece. Pregnancy is still possible in perimenopause, and standard menopausal HRT does not prevent it. There are several ways to prevent pregnancy in perimenopause:

1. Combined hormonal contraception (pill, patch, ring) treats hot flashes and irregular bleeding while preventing pregnancy. ACOG and the Menopause Society support continuing it to age 55 in women without contraindications. [8] Combined oral contraception isn't for everyone: smokers over 35, women with migraine with aura, uncontrolled hypertension, or prior blood clots need another method. [8] In addition, hormonal contraception cannot be titrated or adjusted to optimally relieve perimenopausal symptoms.

2. A levonorgestrel IUD plus low-dose estrogen: the IUD provides contraception and endometrial protection while estrogen addresses symptoms.

3. Abstinence, consistent use of condoms, bilateral tubal ligation, or partner vasectomy are all reasonable contraceptive options that can be considered and coupled with menopausal hormone therapy in perimenopause.

What Will HRT Actually Improve?

Strong evidence

• Hot flashes and night sweats. HRT is the most effective available treatment: more effective than SSRIs/SNRIs, herbal products, CBT, acupuncture, or hypnosis in a network meta-analysis. [1][12] Trials show roughly 2 to 4 fewer hot flashes per day than placebo. [13]

• Vaginal dryness and painful sex. Both systemic and vaginal estrogen help. Importantly, systemic hormone therapy can worsen or cause urinary incontinence, so vaginal estrogen is preferred when dryness and urinary symptoms are the main problem. [1]

• Bone density and fractures. In the WHI, both regimens cut hip fracture risk by about a third. [3] In the USPSTF review, estrogen alone prevented 388 fractures per 10,000 women over 7.2 years. [5] Protection fades after stopping.

Moderate evidence

• Sleep improves modestly, largely indirectly through fewer night sweats.

• Mood and concentration may improve in women who also have hot flashes, but HRT is unlikely to help women without vasomotor symptoms, and it is not a treatment for clinical depression.

• Joint aches, energy, and muscle preservation: plausible and commonly reported, but still needs further research.

Other findings worth knowing: estrogen plus progestin reduced colorectal cancer (34 fewer cases per 10,000 over 5.6 years) and both regimens reduced new type 2 diabetes. These are trial observations, not reasons to start HRT. [3]

The downstream effect is real: better sleep tends to improve mood and focus, more energy makes exercise feasible, and comfort during sex affects relationships. Untreated bothersome symptoms in midlife are associated with reduced quality of life and lower work productivity.

Am I Too Young? Early Menopause and POI

For women with premature ovarian insufficiency (ovarian function declining before 40) or early menopause (40 to 45), hormone therapy isn't optional; it's the standard of care. These women face decades of extra estrogen deficiency, associated with osteoporosis, cardiovascular disease, cognitive problems, and increased all-cause mortality. [9][11]

Guidance is unusually consistent. ACOG, the Menopause Society, NICE, and the International Menopause Society all recommend hormone therapy until at least the average age of natural menopause (about 51). [9][10][11] A 2025 ESHRE/ASRM/IMS guideline made this a STRONG recommendation, whether or not symptoms are present. [11] Two practical points: doses are typically higher than standard postmenopausal doses and because spontaneous ovulation can still occur, HRT does not substitute for contraception. [11]

Women with surgical menopause (ovaries removed) or menopause induced by chemotherapy or radiation are generally managed the same way.

Am I Too Late? Starting After 60

The honest answer: Many women older than 60 can still start transdermal menopausal hormone therapy safely. You deserve a conversation to discuss your individual risks and your possible benefits given your symptoms and personal health history.

The Menopause Society states that for women initiating more than 10 years from menopause or after age 60, the benefit-risk ratio appears less favorable due to greater absolute risks of coronary disease, stroke, clots, and dementia. [1] Several things soften that:

• Age at initiation and current age are different questions. ACOG recommends against routine discontinuation at 65. A woman who started at 51 and is now 66 is in a different position from someone starting fresh at 66.

• Symptoms can persist for decades. Longer durations for documented indications like persistent hot flashes are supported by the Menopause Society, with shared decision-making and periodic reassessment.

• Baseline risk drives absolute risk. A healthy 63-year-old and a 63-year-old with hypertension, obesity, and prior stroke are not in the same situation.

• Route and dose shift the math. Transdermal estradiol has a better clot profile.

• Vaginal estrogen is almost always available. Minimal systemic absorption, recommended for bothersome genitourinary symptoms — including in many women who can't take systemic therapy. Age is not a barrier.

Who Should Avoid Systemic HRT?

Absolute contraindications include estrogen-sensitive cancers (breast, endometrial, or ovarian), severe active liver disease, prior blood clot (situation-dependent), prior stroke or TIA, active cardiovascular disease (heart attack), unexplained vaginal bleeding (which must be evaluated first), pregnancy.

Relative cautions: high cardiovascular risk, uncontrolled hypertension, gallbladder disease (increased with both regimens in trials), migraines with aura, significant obesity, strong family history of breast cancer, or high-risk genetic mutations.

Practice has become more individualized. Route matters (transdermal for elevated clot risk). Hormone type matters: in the WHI, estrogen plus progestin increased invasive breast cancer by about 51 extra cases per 10,000 women over 5.6 years, while estrogen alone did not, [3] and in 20-year follow-up was associated with lower breast cancer risk (HR 0.78). [4] Large observational studies do show increased risk with both types, so randomized and observational data don't fully agree here. Risk rises with longer duration of combined therapy. And for breast cancer survivors with bothersome genitourinary symptoms, low-dose vaginal estrogen may be considered in conjunction with the oncologist.

One more thing worth naming: FDA-approved body-identical products (transdermal estradiol, micronized progesterone) are well studied. Custom-compounded hormones are not FDA-regulated for purity or potency, lack safety data, and are not recommended by the Menopause Society or ACOG. "Bioidentical" and "compounded" are not synonyms.

Quick Answers to Common Questions

Can I start while still having periods?

Yes, perimenopausal treatment is appropriate, but the plan must include contraception if pregnancy is possible.

What if vaginal dryness is my only symptom?

Low-dose vaginal estrogen is the preferred option. It doesn't carry the systemic risk profile, and systemic therapy can actually worsen urinary incontinence.

What if I'm 55?

Comfortably within the favorable window if you're under 60 or within 10 years of your last period.

What if I'm 65?

Starting fresh means a less favorable balance, but it's an individualized decision, and vaginal estrogen remains appropriate. If you're already on therapy, guidelines advise against stopping simply because of a birthday.

Can I stop and restart?

Yes. Symptoms often return on stopping, and reassessment is a normal part of care — the Menopause Society emphasizes periodic reevaluation.

How long can I stay on it?

There's no fixed stopping date. Longer use is supported for documented indications with shared decision-making and periodic review.

The Bottom Line

For most healthy women, starting hormone therapy before age 60 or within 10 years of menopause offers the most favorable balance of benefits and risks; HRT provides the most effective relief available for hot flashes and night sweats, along with bone protection, at low absolute risk levels in this age group. [1] Later initiation isn't forbidden, but it deserves careful consideration. For women with premature or early menopause, treatment until around age 51 is recommended across every major guideline.

What the evidence does not support is taking hormones to prevent heart disease or dementia, or waiting until symptoms become unbearable before asking for help. [5] There's no medal for suffering through it.

Every woman's history, risk profile, and priorities are different, and the right answer at 48 may not be the right answer at 62. If you're experiencing symptoms of perimenopause or menopause and wondering whether now is the right time, working with a clinician who specializes in menopause can help you make an informed decision based on your symptoms, health history, and personal goals. Radiant Health for Women specializes in hormone therapy and takes pleasure in helping women feel like themselves again.

---

References

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767–794. https://journals.lww.com/menopausejournal/fulltext/2022/07000/the_2022_hormone_therapy_position_statement_of_the.4.aspx

2. Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., Stanczyk, F. Z., Selzer, R. H., Azen, S. P., & ELITE Research Group. (2016). Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://www.nejm.org/doi/full/10.1056/NEJMoa1505241

3. Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Margolis, K. L., Wassertheil-Smoller, S., Beresford, S. A., Cauley, J. A., Eaton, C. B., Gass, M., … Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://pubmed.ncbi.nlm.nih.gov/24084921/

4. Manson, J. E., Crandall, C. J., Rossouw, J. E., Chlebowski, R. T., Anderson, G. L., Stefanick, M. L., Aragaki, A. K., Cauley, J. A., Wells, G. L., LaCroix, A. Z., Thomson, C. A., Neuhouser, M. L., Van Horn, L., Kooperberg, C., Howard, B. V., Tinker, L. F., Wactawski-Wende, J., Shumaker, S. A., & Prentice, R. L. (2024). The Women's Health Initiative randomized trials and clinical practice: A review. JAMA, 331(20), 1748–1760. https://doi.org/10.1001/jama.2024.6542

5. Gartlehner, G., Patel, S. V., Reddy, S., Rains, C., Schwimmer, M., & Kahwati, L. (2022). Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 328(17), 1747–1765. https://jamanetwork.com/journals/jama/fullarticle/2797868

6. Harman, S. M., Black, D. M., Naftolin, F., Brinton, E. A., Budoff, M. J., Cedars, M. I., Hopkins, P. N., Lobo, R. A., Manson, J. E., Merriam, G. R., Miller, V. M., Naftolin, F., Neal-Perry, G., Santoro, N. F., Taylor, H. S., Vittinghoff, E., Yan, M., & Hodis, H. N. (2014). Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Annals of Internal Medicine, 161(4), 249–260. https://www.acpjournals.org/doi/10.7326/M14-0353

7. El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., & Allison, M. A. (2020). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000912

8. American College of Obstetricians and Gynecologists. (2019). ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstetrics & Gynecology, 133(2), e128–e150. https://pubmed.ncbi.nlm.nih.gov/30681544/

9. American College of Obstetricians and Gynecologists. (2017). ACOG Committee Opinion No. 698: Hormone therapy in primary ovarian insufficiency. Obstetrics & Gynecology, 129(5), e134–e141. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/05/hormone-therapy-in-primary-ovarian-insufficiency

10. National Institute for Health and Care Excellence. (2024). Menopause: identification and management (NG23). https://www.nice.org.uk/guidance/ng23

11. Panay, N., Anderson, R. A., Bennie, A., Cedars, M., Davies, M., Ee, C., Gravholt, C. H., Kalantaridou, S., Kallen, A., Kim, K. Q., Misrahi, M., Mousa, A., Nappi, R. E., Rocca, W. A., Ruan, X., Teede, H., Vermeulen, N., Vogt, E., Vincent, A. J., & ESHRE, ASRM, CREW-HiRL, and IMS Guideline Group on POI. (2024). Evidence-based guideline: Premature ovarian insufficiency. Human Reproduction Open, 2024(4), hoae065. https://doi.org/10.1093/hropen/hoae065 (co-published in Fertility and Sterility, 2025;123(2):221–236)

12. Sarri, G., Pedder, H., Dias, S., Guo, Y., & Lumsden, M. A. (2017). Vasomotor symptoms resulting from natural menopause: A systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG: An International Journal of Obstetrics & Gynaecology, 124(10), 1514–1523. https://doi.org/10.1111/1471-0528.14619

13. MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, 2004(4), CD002978. https://doi.org/10.1002/14651858.CD002978.pub2